Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme of ESK-001 for treating plaque psoriasis.

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Auron has dosed the first subject in the Phase I trial of AUTX-703, targeting individuals with advanced haematologic ...

Intellia's news comes at a challenging time for gene therapies, as multiple serious adverse events and fatalities have been ...

After Lykos' rejection from the FDA last year, companies trying to navigate the psychedelic drug trial sector face various ...

Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...

Rein Therapeutics has dosed the first subject in a Phase II trial of LTI-03, its lead asset for treating idiopathic pulmonary ...

The FDA ordered a clinical hold on Rocket Pharmaceuticals' Danon disease trial after the adverse event was first disclosed.

Entrada has secured the authorisation within the EU Clinical Trial Regulation to begin the Phase I/II trial of ENTR-601-45.

Gilgamesh managed to overcome the issue of functional unblinding in the study, an obstacle experienced by the psychedelic ...